This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01111/identifier/pharmgkb/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01111/identifier/kegg-compound/
foafhttp://xmlns.com/foaf/0.1/
n23http://linked.opendata.cz/resource/mesh/concept/
n13http://linked.opendata.cz/resource/drugbank/company/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01111/identifier/pubchem-compound/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01111/identifier/pubchem-substance/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01111/identifier/kegg-drug/
n25http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB01111/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01111/identifier/national-drug-code-directory/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n19http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01111
rdf:type
n3:Drug
n3:description
Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms. Colistimethate is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.
n3:dosage
n5:271B414F-363D-11E5-9242-09173F13E4C5 n5:271B4150-363D-11E5-9242-09173F13E4C5 n5:271B414E-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
2-3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.
n3:indication
For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly <i>Pseudomonas aeruginosa</i>.
owl:sameAs
n21:DB01111 n25:DB01111
dcterms:title
Colistimethate
adms:identifier
n8:C13553 n11:DB01111 n12:216258 n14:46508586 n17:D02049 n18:0574-0858-01 n26:PA164749509
n3:mechanismOfAction
Colistimethate is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistimethate is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes.
n3:packager
n13:271B4146-363D-11E5-9242-09173F13E4C5 n13:271B4144-363D-11E5-9242-09173F13E4C5 n13:271B4145-363D-11E5-9242-09173F13E4C5 n13:271B4143-363D-11E5-9242-09173F13E4C5 n13:271B4149-363D-11E5-9242-09173F13E4C5 n13:271B4147-363D-11E5-9242-09173F13E4C5 n13:271B4148-363D-11E5-9242-09173F13E4C5
n3:synonym
Colistin sodium methanesulfonate
n3:toxicity
Oral LD<sub>50</sub> in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.
n9:hasAHFSCode
n10:08-12-28-28
n3:salt
n22:hasConcept
n23:M0045829
foaf:page
n16:colistimethate.html n19:colistimethate.htm
n3:IUPAC-Name
n4:271B4155-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B415B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B415A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4157-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4158-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4159-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B416B-363D-11E5-9242-09173F13E4C5 n4:271B4153-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4151-363D-11E5-9242-09173F13E4C5 n4:271B4154-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4152-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4161-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4162-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B415C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B415D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B415F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B415E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4160-363D-11E5-9242-09173F13E4C5
n3:absorption
Very poor absorption from gastrointestinal tract.
n3:affectedOrganism
Gram-negative bacilli
n3:casRegistryNumber
8068-28-8
n3:category
n3:containedIn
n6:271B414C-363D-11E5-9242-09173F13E4C5 n6:271B414D-363D-11E5-9242-09173F13E4C5 n6:271B414B-363D-11E5-9242-09173F13E4C5 n6:271B414A-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4167-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4169-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B416A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4166-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4165-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4168-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4156-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4163-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4164-363D-11E5-9242-09173F13E4C5